Daphni Blue Raises €260M to Fuel Europe's Science-Driven Startup Revolution

Daphni, a France-based venture capital firm, has successfully closed its Blue fund at €260 million, surpassing its initial target. This achievement underscores the strong investor confidence in Daphni's mission-driven strategy, which focuses on transforming European scientific research into entrepreneurial ventures that tackle major societal and environmental challenges.



In a broader venture capital market that has seen a slowdown, Daphni's ability to reach its final close within nine months is noteworthy. The fund has already made investments in nine deeptech companies, all of which originated from prominent French research institutions. This swift deployment of capital highlights Daphni's growing maturity and the effectiveness of its model, which combines a large entrepreneurial community with a dedicated digital platform.



The Blue fund is built on the conviction that the intersection of science, digital technologies, artificial intelligence, and the physical world will yield many of the next significant technological breakthroughs. To bring these innovations to market, long-term capital and specialized support are essential. Pierre-Eric Leibovici, Founder and Managing Partner of Daphni, emphasized that France and Europe produce a substantial volume of intellectual property across various disciplines, but the transition from laboratory research to commercial application remains underdeveloped and underfunded.



This is where Daphni sees an opportunity: in transforming exceptional scientific capital into technology-driven entrepreneurial ventures that create both economic and societal value. The first portfolio companies under the Blue fund include startups like Owlo, which is developing real-time, non-invasive, label-free 3D microscopy technology, and EverDye, which is advancing a patented textile dyeing technology based on green chemistry.



The implications of Daphni's strategy extend beyond the financial returns; they have the potential to reshape how science-driven innovations are brought to market. For everyday users, this could mean access to groundbreaking technologies that improve healthcare, reduce environmental impact, and enhance quality of life. From an industry perspective, Daphni's approach could set a new standard for venture capital firms, emphasizing the importance of long-term investment in science-driven projects.



As Daphni targets both financial and non-financial performance, a portion of the fund's carried interest is linked to ESG criteria, ensuring alignment between long-term impact and value creation. This commitment to sustainability and societal impact positions Daphni as a leader in the European venture capital landscape, poised to make a significant difference in the years to come.



The Blue fund plans to support around 40 European companies, with Daphni's experience in backing science-based ventures like Epyr, Moonwatt, Pasqal, and Pruna AI demonstrating the value-creation potential of this approach. As the fund continues to deploy its capital, it will be interesting to see the impact of Daphni's investments on the European startup ecosystem and beyond.



In conclusion, Daphni's successful closing of its Blue fund at €260 million is a testament to the firm's vision and the potential of science-driven entrepreneurship in Europe. As the fund supports more startups and helps bring innovative technologies to market, it is likely to have a lasting impact on the region's economy and society.